Norwegian bladder cancer diagnostics company Photocure ASA (OSE: PHO) said on Wednesday that it has signed an agreement with pharmaceutical services provider Clinigen to supply Hexvix through a Named Patient Program (NPP) in more than 40 markets where the product is not approved or commercially available.
Under the agreement, Photocure will supply Hexvix to Clinigen, which will manage worldwide distribution from a UK-based central warehouse.
Hexvix, marketed as Cysview in the US and Canada, is a drug that preferentially accumulates in bladder cancer cells, making them glow bright pink during blue light cystoscopy (BLC) and is designed to improve tumour detection.
The programme allows physicians to request Hexvix for individual bladder cancer patients, in accordance with local regulations, where they determine that BLC using Hexvix may be beneficial. The global initiative follows an initial rollout in South Africa in 2024 and is intended to provide access for patients with suspected or recurrent bladder tumours in countries where Hexvix is not approved or marketed.
Where approved, BLC with Hexvix is used alongside standard white light cystoscopy to support the diagnosis and management of bladder cancer in patients with known or suspected disease.
According to data cited by the company, bladder cancer accounted for 635,000 new cases and more than 227,000 deaths worldwide in 2024, with approximately 1.98 million prevalent cases over five years.
Foventa makes key CMO and CFO appointments
BioCare climbs 1,145 places on Inc. 5000 list
DuPont recognised with R&D 100 Award for innovation in healthcare
Synaptiq Therapeutics launches and acquires clinical-stage SYN-001 programme
WuXi AppTec named to FTSE4Good Index Series for fourth consecutive year
Kibow Biotech receives AANP Corporation of the Year Award
EDX Medical to provide molecular profiling services to Astron Health
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees